Eli Lilly Yönetim

Yönetim kriter kontrolleri 2/4

Eli Lilly CEO'su Dave Ricks, Jan2017 tarihinde atandı, in görev süresi 9.67 yıldır. in toplam yıllık tazminatı $ 36.70M olup, şirket hissesi ve opsiyonları dahil olmak üzere 4.6% maaş ve 95.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.091% ine doğrudan sahiptir ve bu hisseler ARS 1,381.68B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7 yıl ve 10.3 yıldır.

Anahtar bilgiler

Dave Ricks

İcra Kurulu Başkanı

US$36.7m

Toplam tazminat

CEO maaş yüzdesi	4.63%
CEO görev süresi	9.7yrs
CEO sahipliği	0.09%
Yönetim ortalama görev süresi	7yrs
Yönetim Kurulu ortalama görev süresi	10.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dave Ricks'un ücretlendirmesi Eli Lilly'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2026	n/a	n/a	US$27b
Mar 31 2026	n/a	n/a	US$25b
Dec 31 2025	US$37m	US$2m	US$21b
Sep 30 2025	n/a	n/a	US$18b
Jun 30 2025	n/a	n/a	US$14b
Mar 31 2025	n/a	n/a	US$11b
Dec 31 2024	US$29m	US$2m	US$11b
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b

Tazminat ve Piyasa: Dave 'nin toplam tazminatı ($USD 36.70M ), AR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.28M ).

Tazminat ve Kazançlar: Dave 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Dave Ricks (58 yo)

9.7yrs

Görev süresi

US$36,698,337

Tazminat

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Ricks	Chairman	9.7yrs	US$36.70m	0.091% ARS 1.4t
Lucas Montarce	Executive VP & CFO	2yrs	US$8.48m	0.0018% ARS 27.5b
Daniel Skovronsky	Chief Scientific & Product Officer and President of Lilly Research Laboratories	8.3yrs	US$17.79m	0.026% ARS 399.3b
Anat Hakim	Executive VP	6.6yrs	US$9.85m	0.0057% ARS 85.6b
Jacob Van Naarden	Executive VP	no data	US$7.59m	0.0041% ARS 61.5b
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	13.8yrs	Veri yok	0.00037% ARS 5.6b
Diogo Rau	Executive VP and Chief Information & Digital Officer	5.3yrs	US$5.10m	0.0030% ARS 44.7b
Michael Czapar	Senior Vice President of Investor Relations	7.8yrs	Veri yok	Veri yok
Eric Dozier	Executive VP & Chief People Officer	3.8yrs	Veri yok	0.0016% ARS 24.8b
Ilya Yuffa	Executive VP and President of Lilly USA & Global Customer Capabilities	5.9yrs	Veri yok	0.0033% ARS 50.4b
Patrik Jonsson	Executive VP & President of Lilly International	7yrs	US$3.92m	0.0062% ARS 92.9b
Frank Cunningham	Senior Vice President of Global Value & Access	7.1yrs	Veri yok	Veri yok

7.0yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: LLY 'un yönetim ekibi deneyimli ve deneyimlidir ( 7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Ricks	Chairman	9.7yrs	US$36.70m	0.091% ARS 1.4t
Gabrielle Sulzberger	Independent Director	5.7yrs	US$365.50k	0.00033% ARS 5.0b
Sidney Taurel	Chairman Emeritus	17.7yrs	US$13.06m	Veri yok
Jon Erik Fyrwald	Independent Director	20.8yrs	US$343.80k	0.00019% ARS 2.9b
Ralph Alvarez	Independent Director	17.4yrs	US$361.00k	0.000090% ARS 1.4b
Carolyn Bertozzi	Independent Director	less than a year	US$7.68k	0.00022% ARS 3.3b
William Kaelin	Independent Director	14.3yrs	US$392.00k	Veri yok
Mary Hedley	Independent Director	4.3yrs	US$339.00k	0.000040% ARS 604.1m
Juan Luciano	Lead Independent Director	10.6yrs	US$398.00k	0.0019% ARS 28.5b
Katherine Baicker	Independent Director	14.8yrs	US$361.00k	Veri yok
Jamere Jackson	Independent Director	9.9yrs	US$368.00k	0.000020% ARS 302.0m
Kimberly Johnson	Independent Director	5.6yrs	US$336.00k	Veri yok

10.3yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LLY 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/11 14:33
Gün Sonu Hisse Fiyatı	2026/09/11 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Eli Lilly and Company 53 Bu analistlerden 28, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Emily Field	Barclays
Kerry Holford	Berenberg

Eli Lilly Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company Announces Retirement of Anne White as Executive Vice President and President Lilly Neuroscience, Effective from December 31, 2025

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of AtaiBeckley Inc. (NasdaqGM:ATAI) from Apeiron Investment Group Limited, BlackRock, Inc. (NYSE : BLK) and others.

Eli Lilly And Company Reports 52-Week Results From Together-PsO and TOGETHER-PSA Phase 3b Clinical Trials Evaluating Taltz And Zepbound Used Together in Adults with Psoriatic Disease and Obesity

Eli Lilly and Company Updates Earning Guidance for the Year 2026

Eli Lilly and Company Receives Fda Breakthrough Therapy Designation for Olomorasib as Monotherapy for Previously Treated Kras G12c-Mutant Advanced Pancreatic Cancer

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. (NasdaqGM:ATAI) from Apeiron Investment Group Limited and others for $2.6 billion.

Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders.

Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026

Eli Lilly and Company (NYSE:LLY) acquired 4E Therapeutics Inc.

Eli Lilly and Company Receives Fda Approval for EBGLYSS Maintenance Dose Every Eight Weeks in Patients with Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Delivers Superior A1C Control And Weight Loss With Foundayo In Three Pivotal Type 2 Diabetes Trials

Eli Lilly And Company Announces Results From Phase 3 LIBRETTO-432 Clinical Trial Of Retevmo (Selpercatinib) As Adjuvant Therapy Versus Placebo In Patients With Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer

Eli Lilly and Company Presents New Data on Foundayo, Mounjaro and Retatrutide At the American Diabetes Association's 86Th Scientific Sessions

Eli Lilly and Company Announces Expanded Coverage for Foundayo and Zepbound Obesity Medicines

Eli Lilly and Company (NYSE:LLY) entered into an agreement to acquire Curevo, Inc. from HBM Healthcare Investments AG (SWX:HBMN), a fund managed by HBM Partners Ltd., and others for $1.5 billion.

Eli Lilly and Company Showcases Oncology Portfolio Across Tumor Types and Treatment Modalities At the American Society of Clinical Oncology Annual Meeting

Eli Lilly and Company Announces Results of Retatrutide Phase 3 Clinical Trial

Walden Macht Haran & Williams LLP Secures Victory Against Eli Lilly and Company

Eli Lilly and Company Presents Results for Foundayo and Zepbound in Weight Loss Maintenance Trials

Eli Lilly and Company Announces Omvoh Demonstrates Durable Disease Clearance in Ulcerative Colitis Through Four Years

Eli Lilly and Company Raises Earning Guidance for the Year 2026

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.

Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 Billion

Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk

Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLL

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S

Eli Lilly And Company Receives FDA Approval For Foundayo (Orforglipron) For Weight Loss

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.

Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and Obesity

Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 Diabetes

Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options

Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata

Eli Lilly and Company Announces Detailed Results from ACHIEVE-3

Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)

Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)

Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of Retevmo

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian Cancer

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.

Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli Lilly

Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative Colitis

Eli Lilly and Company's Omvoh Demonstrates Early and Sustainable Improvement in Bowel Intention Outcomes for Patients with Ulcerative Colitis

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Eli Lilly and Company Announces Results from the Primary Overall Survival Analysis of the Phase 3 Monarche Trial

Eli Lilly and Company to Report Q3, 2025 Results on Oct 30, 2025

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 Trials

Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery

Eli Lilly and Company's Omvoh (mirikizumab-mrkz) Is the First and Only Interleukin-23p19 (IL-23p19) to Help Patients with Moderately Active Ulcerative Colitis Achieve Sured, Long-Term Outcomes Through Four Years